News

The Phase I clinical study is being carried out in healthy volunteers, who will receive increasing doses of HQK-1001 to evaluate its safety and pharmacokinetics in anticipation of

The company had previously reported that it intended to transition from user preference testing, which had expanded to 34 clinical sites by the end of 2007, to full

The primary purpose of the ‘proof of concept trial’ is to further evaluate the safety and efficacy of SF-1019 in the treatment of diabetic ulceration and its effect

ALT-2074 is one of the company’s lead compounds under development for use in cardiovascular disease. Noah Berkowitz, president and CEO of Synvista Therapeutics, said: “We have identified sites

This randomized, vehicle-controlled study, being conducted in San Antonio, Texas, is enrolling otherwise healthy overweight and obese type 2 diabetic volunteers to evaluate the safety, tolerability, and pharmacokinetics

The company received a CE Mark (European Conformity approval) for the Ulthera System in 2007 and is expecting FDA clearance to sell products in the US. Ulthera will

The open-label Phase I study in patients with solid tumors is designed to identify the maximum tolerated dose of STA-9090 based on a once-a-week, one-hour intravenous dosing schedule.

Under the terms of the agreement, Angiotech has been granted an equity position in Symphony Medical in exchange for the exclusive license of Angiotech’s technology in the field

The Phase III, multinational, randomized, double-blind, placebo-controlled study will enroll 1,100 previously untreated patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). The patients will be